Difference between revisions of "Darbepoetin alfa (Aranesp)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf Darbepoetin alfa (Aranesp) package insert]</ref><ref>[[Media:Darbepoetin.pdf | Darbepoetin alfa (Aranesp) package insert (locally hosted backup)]]</ref><ref>[http://www.aranesp.com/ Aranesp manufacturer's website]</ref> | + | Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf Darbepoetin alfa (Aranesp) package insert]</ref><ref>[[Media:Darbepoetin.pdf | Darbepoetin alfa (Aranesp) package insert (locally hosted backup)]]</ref><ref>[http://www.aranesp.com/ Aranesp manufacturer's website]</ref><ref>As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program</ref> |
<br>Route: SC, IV | <br>Route: SC, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf | + | *[http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf Darbepoetin alfa (Aranesp) package insert]<ref name="insert"></ref> |
*[http://chemocare.com/chemotherapy/drug-info/darbepoetin-alfa.aspx Darbepoetin alfa (Aranesp) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/darbepoetin-alfa.aspx Darbepoetin alfa (Aranesp) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/darbepoetin-alfa.aspx Darbepoetin alfa (Aranesp) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/darbepoetin-alfa.aspx Darbepoetin alfa (Aranesp) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]</ref> | ||
Revision as of 05:27, 14 April 2017
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3][4]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Darbepoetin alfa (Aranesp) package insert[1]
- Darbepoetin alfa (Aranesp) patient drug information (Chemocare)[5]
- Darbepoetin alfa (Aranesp) patient drug information (UpToDate)[6]
Also known as
Nespo
References
- ↑ 1.0 1.1 1.2 Darbepoetin alfa (Aranesp) package insert
- ↑ Darbepoetin alfa (Aranesp) package insert (locally hosted backup)
- ↑ Aranesp manufacturer's website
- ↑ As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Darbepoetin alfa (Aranesp) patient drug information (Chemocare)
- ↑ Darbepoetin alfa (Aranesp) patient drug information (UpToDate)